Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Bittium Corporation - Managers’ Transactions - Petri Toljamo

Bittium CorporationManagers’ Transactions Bittium Corporation - Managers’ Transactions - Petri Toljamo Bittium Corporation, Stock Exchange Release, May 7, 2024, at 10:30 am (CEST+1)  Person subject to the notification requirement Name: Petri Toljamo Position: Member of the Board/Deputy member Issuer: Bittium Oyj LEI: 743700NFG5W5I59OVX65 Notification type: INITIAL NOTIFICATION Reference number: 61330/5/4  Transaction date: 2024-05-02 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009007264 Nature of transaction: RECEIPT OF A

Fayes Investeringar 1 AB publishes supplement to the offer document for the recommended public cash offer to the shareholders of Awardit AB (publ)

The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of shareholders in Australia, Hong Kong, Japan, Canada, New Zealand, South Africa or the United States of America (the “US”), or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law or

Bittium Corporation - Managers’ Transactions - Riitta Tiuraniemi

Bittium CorporationManagers’ Transactions Bittium Corporation - Managers’ Transactions - Riitta Tiuraniemi Bittium Corporation, Stock Exchange Release, May 7, 2024, at 10:30 am (CEST+1)  Person subject to the notification requirement Name: Riitta Tiuraniemi Position: Member of the Board/Deputy member Issuer: Bittium Oyj LEI: 743700NFG5W5I59OVX65 Notification type: INITIAL NOTIFICATION Reference number: 61327/5/4  Transaction date: 2024-05-02 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009007264 Nature of transaction:

Bittium Corporation - Managers’ Transactions - Raimo Jyväsjärvi

Bittium CorporationManagers’ Transactions Bittium Corporation - Managers’ Transactions - Raimo Jyväsjärvi Bittium Corporation, Stock Exchange Release, May 7, 2024, at 10:30 am (CEST+1)  Person subject to the notification requirement Name: Raimo Jyväsjärvi Position: Member of the Board/Deputy member Issuer: Bittium Oyj LEI: 743700NFG5W5I59OVX65 Notification type: INITIAL NOTIFICATION Reference number: 61332/4/4  Transaction date: 2024-05-02 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009007264 Nature of transaction:

Bittium Corporation - Managers’ Transactions - Veli-Pekka Paloranta

Bittium CorporationManagers’ Transactions Bittium Corporation - Managers’ Transactions - Veli-Pekka Paloranta Bittium Corporation, Stock Exchange Release, May 7, 2024, at 10:30 am (CEST+1)  Person subject to the notification requirement Name: Veli-Pekka Paloranta Position: Member of the Board/Deputy member Issuer: Bittium Oyj LEI: 743700NFG5W5I59OVX65 Notification type: INITIAL NOTIFICATION Reference number: 61326/4/4  Transaction date: 2024-05-02 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009007264 Nature of transaction:

Gradientech receives patent rights in China

The diagnostics company Gradientech reports having received a Notification to Grant Patent Rights in China for its QuickMIC® cassette, the single-use test device in the QuickMIC® diagnostic system for ultra-rapid antibiotic susceptibility testing (AST).Gradientech announces that the State Intellectual Property Office (SIPO) of P. R. China has recognised the originality of the QuickMIC® cassette construction to be used in automated systems for antibiotic susceptibility testing of microorganisms. The Chinese patent application is based on the International Publication Number WO 2020/204799

Notice of Annual General Meeting in Jetpak Top Holding AB (publ)

The shareholders of Jetpak Top Holding AB (publ), reg. no. 559081-5337, (the "Company"), are hereby convened to the annual general meeting to be held on Tuesday 11 June 2024 at 2 pm. in Törngren Magnell & Partners Advokatfirma’s offices on Jakobs Torg 3 in Stockholm.   Right to attend the annual general meeting and notice Shareholders wishing to attend the annual general meeting must:   i. on the record date, which is Friday 31 May 2024, be registered in the share register maintained by Euroclear Sweden AB; and   ii. notify their participation and any assistants (no

Inwido among Europe’s climate leaders 2024

Inwido claims an honorable place on prestigious Financial Times Sustainability list.The Financial Times has compiled a list of Europe's 500 climate leaders 2024 . Inwido earns a spot in the top half of the list and ends up in 11th place in the segment - Construction & Building materials. Among the almost 50 Swedish companies that make it onto the list, Inwido holds a nice 18th place. "We are very happy about our position among Europe's climate leaders. For Inwido, climate work is assigned a high priority and we have set the goal of

Mandatum plc has received the necessary regulatory approvals to implement the Saxo transaction

Mandatum plc, press release, May 7, 2024 at 9:55 a.m. EEST Mandatum plc and Sampo plc agreed in connection with the partial demerger that Mandatum will purchase Sampo’s shares in Saxo Bank A/S. These shares represent 19.83 percent of all Saxo Bank’s shares. The transaction was conditional on customary consents and regulatory approvals for the transaction. Mandatum received all the necessary regulatory approvals to purchase Sampo’s holdings in Saxo Bank A/S. The transaction is expected to be completed by May 15, 2024.Additional information Media enquiries: Niina Riihelä

Brain+ A/S announce a partially secured rights issue of units of approximately DKK 8.94 million to fund operations and execution of its UK commercialization plan

Copenhagen, Denmark, 7 May 2024 – Brain+ A/S (Nasdaq First North: BRAINP)  This announcement constitutes inside information that Brain+ A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU no. 596/2014). The information was submitted for publication by the contact person below on 7 May 2024.  NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE,

BioStock: Spago’s CEO - "Advancing the Tumorad programme comes first"

Spago Nanomedical’s Q1 report signals steady progress with its radiopharma pipeline. Lead programme Tumorad recently got a boost by the release of positive non-clinical data in a triple-negative breast cancer model, incentivising the company to strengthen its management. – 2024 has begun in the same positive spirit as we ended last year. Given the progress within both of our development programmes, we have seen a need to strengthen the company's organisation, says Spago’s CEO Mats Hansen.Read the article at biostock.se: Spago’s CEO: Advancing the Tumorad programme comes first -

ADDvise Group plans to change listing venue to Nasdaq Stockholm main market

ADDvise Group AB (publ) ("ADDvise Group") has initiated the process of listing the company's A and B shares on Nasdaq Stockholm. The change of listing venue is expected to be completed in the first quarter of 2025. As part of the continued development of ADDvise Group, the company has for some time reviewed the possibility of changing its listing venue from Nasdaq First North to Nasdaq Stockholm main market. The Board of Directors believes that a change of listing venue would be beneficial for the company's continued development, provide a broader capital allocation toolkit, and increase

Invitation to presentation of BioArctic’s first quarter report for January - March 2024 on May 17 at 9:30 a.m. CET

Stockholm, Sweden, May 7, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s first quarter report for January – March 2024 on Friday, May 17, 2024, at 08:00 a.m. CET.In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on May 17, at 09:30 CET, where Gunilla Osswald, CEO, and Anders Martin-Löf, CFO, will present BioArctic and comment on the first quarter report for January – March 2024, followed by a Q&A-session. If you wish to participate via webcast, please use the link below. Via

InCoax Networks AB Interim Report, January – March 2024

InCoax started 2024 with the strongest quarter in the company's history, featuring increased sales, maintained gross margin, improved operational cash flow, and a positive net result. The collaboration with Nokia paves the way for increased growth over time.Financial performance January – March 2024 · Net sales amounted to SEK 30,793,125 (12,931,661). Sales was driven by for the quarter large sales to a US-based FiberLAN operator. · Operating profit amounted to SEK 4,344,935 (-3,082,507), a change driven by an increase in sale. · Earnings after tax amounted to SEK 4,326,106 (–

Presentation of the interim report January - March 2024 on May 14

GARO will publish its report for the first quarter 2024 at 14.00 CET on May 14. Conference call at 15.00 CETThe company will host a conference call at 15.00 CET the same day. The conference will be hosted by Patrik Andersson, President & CEO and Helena Claesson, Chief Financial Officer. Dial in numbers:Sweden: +46 10 884 80 16International: Dail in numbers ID number (access code): 32 42 87 The presentation material will be published at www.garo.se prior to the conference call. The conference will also be audio

Prevas Publishes Interim Report January-March for 2024

Strong quarter and establishment of a strategic platform in Finland. Just like the second half of 2023, we see high demand in growth areas such as energy, electrification, sustainability, defense, embedded systems and cybersecurity.Prevas reports a strong first quarter despite a continued challenging market. Turnover for the first quarter increased by 3.2% to SEK 407.1 million (394.3). Organic growth during the quarter amounted to approximately 40 percent of total growth. We delivered an EBITA of SEK 53.5 million (59.7) and an EBITA margin of 13.2 percent (15.1). The EBITA margin is well

Vacuum distributor in Mexico has become part of Atlas Copco Group

Nacka, Sweden, May 7, 2024: The acquisition of the vacuum related assets and the brand of Mexican Montajes Electromecánicos e Ingeniería, S.A. de C.V. (“MEISA”) has been completed and is now a part of Atlas Copco Group.MEISA provides vacuum pumps and related services to industrial customers in Mexico, the company was founded in 1985 and is located in Queretaro and Monterrey, Mexico. 52 employees joined Atlas Copco Group as part of this acquisition. The purchase price is not disclosed. The acquired business has become part of the Vacuum Technique Service Division within the Vacuum

Repurchases of shares during week 18, 2024

Between 29 April and 3 May 2024 Attendo AB (LEI code 549300KEJDL2FNITUW65) (“Attendo”) has repurchased in total 187,933 own shares (ISIN: SE0007666110) as part of the repurchase program initiated by the Board.The repurchases form part of the repurchase program of a maximum of 16,138,659 own shares for a total maximum amount of SEK 110,000,000 that Attendo announced on 24 April 2024. The repurchase program, which runs between 29 April 2024 and 18 July 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated Regulation (EU) No

Elypta, a Swedish company using metabolism-based liquid biopsy for early detection of cancer, appoints Dr. Eva Pisa to Board of Directors

Stockholm, May 7, 2024: Elypta, a Swedish cancer detection company aiming to commercialize the first metabolism-based liquid biopsy for early detection of cancer, today announced the appointment of Dr. Eva Pisa to its Board of Directors.“I am very much looking forward to working with the team at Elypta in the exciting field of early cancer detection. The team is working on a mass-spectrometer based detection platform where I see a great opportunity as the technology expands into routine use,” says Dr. Pisa.  “I am pleased that Dr Eva Pisa has decided to join the board of Elypta. With her

SmartCraft ASA (SMCRT) re-initiates share buy-back programme

Following the Annual General Meeting the Company has decided to re-initiate a Company share buy-back programme. The buy-back programme will be conducted in accordance with the authorization granted to the board of directors by the Company’s Annual General Meeting held on 2 May 2024. The share buy-back programme will be for a maximum consideration of NOK 15 million. The repurchases will be conducted in the period from 7 May 2024 until the day before the issuer’s Annual General Meeting in 2025, or until the maximum consideration have been reached. Buy-back transactions will be executed

BioStock: Chordate Medical receives patent approval in the US

Chordate Medical will be granted a fourth patent in the US for the migraine treatment Ozilia. In parallel, work is underway to obtain market approval from the FDA. BioStock reached out to CEO Anders Weilandt to learn more about the opportunities in the US market.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/chordate-medical-receives-patent-approval-in-the-us/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nanoformed High-Concentration Biologics Formulation for Subcutaneous Delivery Results to be Presented by Takeda at DDF Summit

Press Release Nanoform Finland Plc May 7, 2024 09.10 EEST / 08.10 CEST Nanoformed High-Concentration Biologics Formulation for Subcutaneous Delivery Results to be Presented by Takeda at DDF Summit Helsinki, Finland – May 7, 2024 – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced that Andreas Liebminger, Ph.D., Global Head of Plasma-derived Therapies Pharmaceutical Sciences, Takeda, is to present data obtained in a proof of concept study, conducted in collaboration with Nanoform, during his presentation titled, “Case Study of a

Interim Report, January - March 2024 (correction of year)

Continued growth in the service business and increased profitabilityJanuary - March 2024 · Revenues decreased by 2.4 per cent to SEK 1,191.3 million (1,220.3).  · Adjusted EBITA increased by 66.4 per cent and amounted to SEK 94.5 million (56.8), corresponding to an adjusted EBITA margin of 7.9 per cent (4.7).  · Earnings before tax amounted to SEK 76.2 million (37.3). · Earnings after tax amounted to SEK 60.7 million (27.9). · Earnings per share amounted to SEK 2.22 (1.02). · New contracts relating to cloud services worth SEK 182.7 million (116.6) were contracted, an

Raute Corporation - Manager's transactions – Halttunen Ville

Raute Corporation, Manager’s transactions, May 7, 2024, at 9:00 a.m. Raute Corporation – Manager’s transactions – Halttunen Ville ____________________________________________ Person subject to the notification requirement Name: Ville Halttunen Position: Chief Financial Officer Issuer: Raute Oyj LEI: 743700G00629V99PE435 Notification type: INITIAL NOTIFICATION Reference number: 61671/4/4 ____________________________________________ Transaction date: 2024-05-06 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009004741 Nature of

There are no items matching the current filter
There are no more items matching the current filter
Back to top